Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06439901
Recruiting Not applicable

Optimizing Bronchopulmonary Cancer Screening

NCT06439901 · tracked via the Priya Life Science France tracker
Sponsor
Institut Curie
Phase
Not applicable
Started
2025-01-27
Last updated
2026-09-10

Condition(s) studied

Bronchopulmonary DiseaseDiagnoses Disease

Investigational drug(s) / intervention(s)

ScreeningInclusionChest CTscan and follow-up

Screening: A first step to identify and recruit people eligible for screening,

Inclusion: A second step for inclusion of participants, with an online self-questionnaire and information, and an inclusion visit to the health center,

Chest CTscan and follow-up: A third step with an initial CTscan, with dual interpretation and appropriate management of participants, including follow-up care.

Study summary

The aim of this study is to evaluate the feasibility of performing a first screening for bronchopulmonary cancer by thoracic scanner in a French cohort within a dedicated, effective and structured network in the pilot centers participating in the study.

Eligibility

Sex
ALL
Min age
50 Years
Max age
74 Years
Healthy volunteers
No
Inclusion Criteria: * Participant aged 50 to 74. * Resident in the Île-de-France region. * Active smoker or quit smoker for 10 years or less: 1. more than 10 cigarettes a day for more than 30 years, 2. more than 15 cigarettes a day for more than 25 years. * The participant has been informed and has signed the consent form. * Social Security System affiliation. * Willingness to participate in a smoking cessation program, if currently smoking. Exclusion Criteria: * Active cancer or a history of cancer in remission for less than 5 years (except basal cell carcinoma of th skin or epithelioma in situ of the uterine cervix). * Presence of symptoms suggestive of bronchopulmonary cancer. Participants with these symptoms require immediate diagnostic investigations and are therefore not eligible for screening. * Weight \>= 140 kg. * Severe comorbidity contraindicating therapeutic options or invasive thoracic diagnostic investigations. * Inability to climb two flights of stairs without stopping. * A thoracic CTscan performed within the previous year. * Persons deprived of liberty or under guardianship. * Impossibility to undergo the medical monitoring of the trial for geographical, social or psychological reasons.

Primary outcome measure(s)

  • Rate of first CTscan for bronchopulmonary cancer screening — 36 months
    Rate of completion of a first bronchopulmonary cancer screening among people who have joined the program (i.e. registered on the program's web platform and met the inclusion criteria).

Trial sites (9)

FacilityCityRegionStatus
Centre CTPS Bobigny Bondy Bobigny France Not Yet Recruiting
Centre Municipal de Santé de Gentilly Gentilly France Not Yet Recruiting
Centre Municipal de Santé Simone Veil Issy-les-Moulineaux France Recruiting
Centre Municipal de Santé Jacqueline Akoun-Cornet Malakoff France Not Yet Recruiting
Centre Municipal de Santé Maurice Ténine Malakoff France Recruiting
Centre de Santé Square de la Mutualité Paris France Recruiting
Institut Curie Paris France Not Yet Recruiting
Institut Mutualiste Montsouris Paris France Not Yet Recruiting
Centre de Santé MGEN Paris France Recruiting

More Institut Curie trials in France

Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures Active, not recruiting
Skin Reactions Related to Thoracic Implantable Chamber Dressings Recruiting
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) Active, not recruiting
Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) Recruiting
Screening and Care for Fear of Cancer Recurrence in Patients With Cancer at Institut Curie Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06439901 on ClinicalTrials.gov ↗ ← All trials in France